l research community has long regarded a pill for MS as an ultimate goal, but so far attempts to develop a safe, feasible, orally available drug candidate have failed. Our team has successfully modified the tetracycline molecule, keeping the core structure that confers anti-MS activity while removing portions of the molecule with antibacterial effects. This represents an exciting advance not only for MS, but potentially for many other inflammation-related disease areas. "
Dr. Michael Draper, Associate Director at Paratek, stated, "Paratek has developed world-class expertise in modifying the tetracycline class, which has a 30-year track record in the marketplace and a favorable, well-documented safety profile. This new, proprietary class of non-antibacterial tetracycline compounds will avoid the negative consequences associated with long-term antibiotic use and will not further contribute to the development of antibiotic resistance. We believe that these highly active, orally available compounds will also prove to be well-tolerated for MS, and we are very proud of this accomplishment."
Page: 1 2 Related biology news :1
Contact: Katie Compa
. Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels2
. Progenika Biopharma presents a biochip that guarantees safety in blood transfusions3
. SNM presents awards on Capitol Hill4
. ESA presents the sharpest ever satellite map of Earth5
. New book presents neurobiology from an evolutionary perspective6
. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants7
. Childrens Hospital and Research Center-Oakland presents a new maternal diet study8
. USGS presents a world of science at GSA in Philadelphia9
. Childrens Hospital Boston presents at the 2006 American Academy of Pediatrics National Conference10
. DFG presents the 2006 MAK and BAT value list11
. Childrens Hospital Boston presents at the 2006 Pediatric Academic Societies annual meeting